Tag Archives: SEC

Kineta: Creative Financing Bridges the "Valley of Death"

At a time when burst bubbles have created uncertainty for investors in the biomedical realm, it’s smart for a drug company to make use of new legislation and emerging trends in venture capital. This is particularly true in spurring confidence in that translational area of drug development many deem the “Valley of Death”. PharmExec caught […]
Posted in Biotech, Deals, leadership, R&D, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , | Leave a comment

SEC Charges Lilly with Corruption Abroad: A Taste of Fines to Come

The Securities and Exchange Commission filed charges on Eli Lilly and Co. yesterday for violations of the Foreign Corrupt Practices Act (FCPA) that allege the drug maker’s subsidiaries overseas bribed foreign officials in Russia, China, Brazil and Poland. The settlement totaled $29 million after an investigation of activities reaching as far back as 1994, assessed […]
Posted in Emerging Markets, Global, Legal, Regulatory | Tagged | 1 Comment
  • Categories

  • Meta